Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050220 | 1.00 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1323564 | 1.00 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1472102 | 0.96 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL22204407 | 0.89 | KDM4E (0.46) | TSHRKDM4ECNR2 | |
| SCHEMBL6228019 | 0.85 | HRH3 (0.37) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29221097 | 0.85 | BCHE (0.39) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL23498992 | 0.85 | OXTR (0.41) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL23498743 | 0.85 | OXTR (0.41) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL44458 | 0.82 | ALDH1A1 (0.39) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL15314659 | 0.82 | ALDH1A1 (0.39) | LMNATDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119053610-A | 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors | 艾伯维公司 | 2024-11-29 | — | — | CN | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4073051-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | Eli Lilly and Company (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| EP-2705028-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | LMNA 1548/4885TDP1 2918/4885MEN1 3252/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | LMNA 975/4885TDP1 1821/4885MEN1 3741/4885 |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | LMNA 975/4885TDP1 1821/4885MEN1 3741/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | LMNA 964/4885TDP1 1854/4885MEN1 3779/4885 |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | CYP2C9, CYP3A5, CYP2J2 | LMNA 208/4885TDP1 3353/4885MEN1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.